FBIOP
Fortress Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$18.75
+1.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 68.5M | 63.3M | 57.7M | 84.5M | 75.7M |
| Cost of Revenue | 25.7M | 20.9M | 20.9M | 22.9M | 30.8M |
| Gross Profit | 42.8M | 42.3M | 36.8M | 61.6M | 45.0M |
| Operating Expenses | |||||
| R&D Expense | 1.2M | 11.9M | 56.9M | 106.1M | 134.9M |
| SG&A Expense | 68.8M | 96.4M | 87.7M | 91.0M | 113.7M |
| General & Admin Expense | 20.8M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.1M | 4.3M | 2.6M | 6.9M | — |
| Total Operating Expenses | 72.2M | 112.6M | 147.2M | 204.0M | 248.5M |
| Cost and Expenses | 97.8M | 133.5M | 168.1M | 226.9M | 279.3M |
| Operating Income (EBIT) | (29.3M) | (70.2M) | (110.4M) | (142.3M) | (203.6M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 2.5M | 2.7M | 3.0M | 1.4M |
| Interest Expense | 9.0M | 8.7M | 9.9M | 12.5M | 13.6M |
| Net Interest Income | (5.4M) | (6.2M) | (7.2M) | (9.5M) | (12.2M) |
| Other Non-Op Income/Expense | 175.2M | 36.7M | (10.2M) | (11.3M) | (9.9M) |
| Non-Operating Income (excl Interest) | (184.1M) | (45.4M) | (1.4M) | (624.0K) | (517.0K) |
| EBT (Pre-Tax Income) | 145.8M | (33.5M) | (120.5M) | (153.6M) | (213.5M) |
| Income Tax Expense | 4.6M | (620.0K) | 312.0K | 521.0K | 449.0K |
| Bottom Line | |||||
| Net Income | 111.8M | 6.8M | (46.0M) | (60.6M) | (86.6M) |
| Earnings from Cont. Ops | 141.2M | (32.9M) | (120.9M) | (154.2M) | (213.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 103.4M | (1.9M) | (55.9M) | (68.7M) | (94.6M) |
| Per Share | |||||
| Basic EPS | $3.27 | ($0.07) | ($2.69) | ($8.47) | ($14.55) |
| Diluted EPS | $2.68 | ($0.05) | ($2.69) | ($8.47) | ($14.55) |
| Revenue Per Share | $2.16 | $2.27 | $2.77 | $10.42 | $12.78 |
| Shares | |||||
| Basic Shares Outstanding | 31.7M | 27.9M | 20.8M | 8.1M | 5.9M |
| Diluted Shares Outstanding | 37.0M | 35.8M | 20.8M | 8.1M | 5.9M |
| Profitability Metrics | |||||
| EBITDA | 159.8M | (20.2M) | (104.5M) | (135.7M) | (193.7M) |
| D&A | 5.0M | 4.7M | 4.5M | 6.0M | 9.4M |
| EBIT | 154.8M | (24.8M) | (109.0M) | (141.7M) | (203.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026